Sanctuary Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.53M Buy
19,611
+6,704
+52% +$457K 0.01% 1189
2026
Q1
$834K Sell
12,907
-16,543
-56% -$1.17M ﹤0.01% 1443
2025
Q4
$1.98M Buy
29,450
+2,112
+8% +$142K 0.01% 938
2025
Q3
$2M Buy
27,338
+235
+0.9% +$15.6K 0.01% 895
2025
Q2
$1.41M Sell
27,103
-5,277
-16% -$300K 0.01% 1029
2025
Q1
$2.07M Sell
32,380
-2,106
-6% -$122K 0.01% 767
2024
Q4
$1.95M Sell
34,486
-2,553
-7% -$131K 0.01% 876
2024
Q3
$1.81M Buy
37,039
+16,511
+80% +$947K 0.01% 915
2024
Q2
$792K Buy
+20,528
New +$900K 0.01% 1333

Other funds holding HALO

Sanctuary Advisors's HALO Position: Q2 2026 in Review

Sanctuary Advisors increased its Halozyme (HALO) stake by 52% in Q2 2026, buying an estimated $457K and bringing the position to 19,611 shares worth $1.53M. The position accounts for 0.01% of the portfolio, ranked #1189.

Sanctuary Advisors first reported a position in HALO in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.07M in Q1 2025. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Sanctuary Advisors held 19,611 shares of Halozyme worth $1.53M as of Q2 2026.
  • Sanctuary Advisors bought 6,704 Halozyme shares in Q2 2026, an estimated $457K.
  • Halozyme made up 0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #1189 holding.
  • Sanctuary Advisors first reported a position in Halozyme in Q2 2024 and has held it in 9 quarters since.
  • Sanctuary Advisors's Halozyme position peaked at $2.07M in Q1 2025.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.